SlideShare a Scribd company logo
Drugs That Affect the Circulatory System
Learning Objectives ,[object Object],[object Object],[object Object],[object Object]
Components and Function of the Circulatory System ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Normal Blood Circulation ,[object Object],[object Object],[object Object],[object Object],[object Object]
Components and Function of the Circulatory System
Drugs That Affect the Heart ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Uses for Cardiac Drugs ,[object Object],[object Object],[object Object],[object Object]
Heart Failure ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Drugs That Affect the Heart ,[object Object],[object Object],[object Object],[object Object],[object Object]
Diuretic Agents ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Inotropic Drugs ,[object Object],[object Object],[object Object]
Inotropic Drugs ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
ACE Inhibitors ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
ACE Inhibitors ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Beta-Blocking Agents ,[object Object],[object Object],[object Object],[object Object]
Beta-Blocking Agents ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Angiotensin II Receptor–Blocking Agents ,[object Object],[object Object],[object Object]
Angiotensin II Receptor–Blocking Agents ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Aldosterone Inhibitor Agents ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Cardiac Arrhythmias ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Drug Used to Treat Arrhythmias ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Drug Used to Treat Arrhythmias ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object]
Learning Objectives ,[object Object],[object Object],[object Object],[object Object]
Vasoconstricting Agents  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Vasoconstricting Agents ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Vasodilating Agents  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Antihypertensive Agents  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Treatment of Hypertension ,[object Object],[object Object],[object Object],[object Object]
Antihypertensive Drug Classes ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Antihypertensive Agents ,[object Object],[object Object],[object Object],[object Object]
Antihypertensive Agents ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Antihypertensive Agents ,[object Object],[object Object],[object Object],[object Object],[object Object]
Antihypertensive Agents ,[object Object],[object Object],[object Object],[object Object],[object Object]
Antihypertensive Agents ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object]
Learning Objectives ,[object Object],[object Object],[object Object],[object Object],[object Object]
Coagulant Agents ,[object Object],[object Object],[object Object],[object Object]
Coagulant Agents ,[object Object],[object Object],[object Object],[object Object],[object Object]
Anticoagulant Agents ,[object Object],[object Object],[object Object]
Heparin ,[object Object],[object Object],[object Object],[object Object]
Heparin ,[object Object],[object Object],[object Object]
Low–Molecular-Weight Heparin Agents ,[object Object],[object Object],[object Object],[object Object]
Low–Molecular-Weight Heparin Agents ,[object Object],[object Object],[object Object],[object Object]
Direct Inhibitors of Thrombin ,[object Object],[object Object],[object Object],[object Object]
Coumarin Anticoagulant Agents ,[object Object],[object Object],[object Object],[object Object]
Coumarin Anticoagulant Agents ,[object Object],[object Object],[object Object],[object Object]
Thrombolytic Therapy for Myocardial Infarction ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object]
Learning Objectives ,[object Object],[object Object],[object Object]
Antiplatelet Therapy in Cardiovascular Disease  ,[object Object],[object Object],[object Object],[object Object],[object Object]
Antiplatelet Therapy in Cardiovascular Disease ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Antilipidemic Drugs  ,[object Object],[object Object],[object Object],[object Object]
Antilipidemic Drugs ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Antilipidemic Drugs ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

More Related Content

What's hot

Dic- disseminated intravascular coagulation
Dic- disseminated intravascular coagulation Dic- disseminated intravascular coagulation
Dic- disseminated intravascular coagulation
bhartisharma175
 
IVMS-CV-Pharmacology- Management of Congestive Heart Failure
IVMS-CV-Pharmacology- Management of Congestive Heart FailureIVMS-CV-Pharmacology- Management of Congestive Heart Failure
IVMS-CV-Pharmacology- Management of Congestive Heart Failure
Imhotep Virtual Medical School
 
Anticoagulants Nursing esther
Anticoagulants Nursing estherAnticoagulants Nursing esther
Anticoagulants Nursing esther
Esther Mary Mathew
 
Respiratory Drugs
Respiratory DrugsRespiratory Drugs
Respiratory Drugs
guest9bc2b8
 
Anti coagulants
Anti coagulantsAnti coagulants
Anti coagulants
samiya shaik
 
Antihypertensive drugs
Antihypertensive drugsAntihypertensive drugs
Antihypertensive drugs
BONI RAFI
 
Scorpion sting management
Scorpion sting managementScorpion sting management
Scorpion sting management
Sindhuja Sompalli
 
25.anticoagulants
25.anticoagulants  25.anticoagulants
25.anticoagulants
Dr.Manish Kumar
 
Digoxin
DigoxinDigoxin
Digoxin
blessy rachel
 
Atenolol Presentation Clin 210 50
Atenolol   Presentation Clin 210 50Atenolol   Presentation Clin 210 50
Atenolol Presentation Clin 210 50Dr.RAJEEV KASHYAP
 
A Rare Case of Kidney Failure Due to Diazoxide Toxicity – Discussion.
A Rare Case of Kidney Failure Due to Diazoxide Toxicity – Discussion.A Rare Case of Kidney Failure Due to Diazoxide Toxicity – Discussion.
A Rare Case of Kidney Failure Due to Diazoxide Toxicity – Discussion.drrkmin
 
Warfarin
WarfarinWarfarin
Hypovolemic shock
Hypovolemic shockHypovolemic shock
Hypovolemic shock
NaderAnush1
 
Antihistamines
AntihistaminesAntihistamines
Anticoagulants naser
Anticoagulants naserAnticoagulants naser
Anticoagulants naserNaser Tadvi
 
PHARMACOLOGY OF ANTIDIURETICS
PHARMACOLOGY OF ANTIDIURETICS   PHARMACOLOGY OF ANTIDIURETICS
PHARMACOLOGY OF ANTIDIURETICS
paramesh Researcher
 

What's hot (20)

Dic- disseminated intravascular coagulation
Dic- disseminated intravascular coagulation Dic- disseminated intravascular coagulation
Dic- disseminated intravascular coagulation
 
IVMS-CV-Pharmacology- Management of Congestive Heart Failure
IVMS-CV-Pharmacology- Management of Congestive Heart FailureIVMS-CV-Pharmacology- Management of Congestive Heart Failure
IVMS-CV-Pharmacology- Management of Congestive Heart Failure
 
Anticoagulants Nursing esther
Anticoagulants Nursing estherAnticoagulants Nursing esther
Anticoagulants Nursing esther
 
Cardiogenic shock
Cardiogenic shockCardiogenic shock
Cardiogenic shock
 
Respiratory Drugs
Respiratory DrugsRespiratory Drugs
Respiratory Drugs
 
Anti coagulants
Anti coagulantsAnti coagulants
Anti coagulants
 
Antihypertensive drugs
Antihypertensive drugsAntihypertensive drugs
Antihypertensive drugs
 
Dic
DicDic
Dic
 
Scorpion sting management
Scorpion sting managementScorpion sting management
Scorpion sting management
 
25.anticoagulants
25.anticoagulants  25.anticoagulants
25.anticoagulants
 
Digoxin
DigoxinDigoxin
Digoxin
 
Ccf
CcfCcf
Ccf
 
Atenolol Presentation Clin 210 50
Atenolol   Presentation Clin 210 50Atenolol   Presentation Clin 210 50
Atenolol Presentation Clin 210 50
 
A Rare Case of Kidney Failure Due to Diazoxide Toxicity – Discussion.
A Rare Case of Kidney Failure Due to Diazoxide Toxicity – Discussion.A Rare Case of Kidney Failure Due to Diazoxide Toxicity – Discussion.
A Rare Case of Kidney Failure Due to Diazoxide Toxicity – Discussion.
 
Warfarin
WarfarinWarfarin
Warfarin
 
Hypovolemic shock
Hypovolemic shockHypovolemic shock
Hypovolemic shock
 
Antihistamines
AntihistaminesAntihistamines
Antihistamines
 
Cardiac emergency ppt
Cardiac emergency pptCardiac emergency ppt
Cardiac emergency ppt
 
Anticoagulants naser
Anticoagulants naserAnticoagulants naser
Anticoagulants naser
 
PHARMACOLOGY OF ANTIDIURETICS
PHARMACOLOGY OF ANTIDIURETICS   PHARMACOLOGY OF ANTIDIURETICS
PHARMACOLOGY OF ANTIDIURETICS
 

Viewers also liked

Pharmacology Git Drugs
Pharmacology   Git DrugsPharmacology   Git Drugs
Pharmacology Git Drugs
pinoy nurze
 
Vasodilators
VasodilatorsVasodilators
Vasodilators
Dr. Advaitha MV
 
Drugs acting on the cns
Drugs acting on the cnsDrugs acting on the cns
Drugs acting on the cns
Mesfin Mulugeta
 
Pharmacology powerpoint git drugs
Pharmacology powerpoint  git drugsPharmacology powerpoint  git drugs
Pharmacology powerpoint git drugsFred Ecaldre
 
Drugs acting on the gastrointestinal tract
Drugs acting on the gastrointestinal tractDrugs acting on the gastrointestinal tract
Drugs acting on the gastrointestinal tractBruno Mmassy
 

Viewers also liked (8)

Pharmacology Git Drugs
Pharmacology   Git DrugsPharmacology   Git Drugs
Pharmacology Git Drugs
 
Vasodilators
VasodilatorsVasodilators
Vasodilators
 
Vasodilators
VasodilatorsVasodilators
Vasodilators
 
Drugs acting on the cns
Drugs acting on the cnsDrugs acting on the cns
Drugs acting on the cns
 
Drugs that act on CNS
Drugs that act on CNSDrugs that act on CNS
Drugs that act on CNS
 
Pharmacology powerpoint git drugs
Pharmacology powerpoint  git drugsPharmacology powerpoint  git drugs
Pharmacology powerpoint git drugs
 
Drugs acting on the gastrointestinal tract
Drugs acting on the gastrointestinal tractDrugs acting on the gastrointestinal tract
Drugs acting on the gastrointestinal tract
 
L1: Drugs acting on the ANS
L1: Drugs acting on the ANSL1: Drugs acting on the ANS
L1: Drugs acting on the ANS
 

Similar to Drugs affecting the circulatory system

Common Medications
Common MedicationsCommon Medications
Common Medicationsmrevader
 
Cardio Vascular Drugs
Cardio Vascular Drugs Cardio Vascular Drugs
Cardio Vascular Drugs
RimshaShafeeq1
 
Cardiac Medications #4 08
Cardiac Medications #4 08Cardiac Medications #4 08
Cardiac Medications #4 08gerlam
 
1. Anti hypertensive drugs.pptx what's hypertension
1. Anti hypertensive drugs.pptx what's hypertension1. Anti hypertensive drugs.pptx what's hypertension
1. Anti hypertensive drugs.pptx what's hypertension
Khyber medical university
 
Atherosclerosis2-Risk factors,Microorganisms,Medications,Classification,Surgi...
Atherosclerosis2-Risk factors,Microorganisms,Medications,Classification,Surgi...Atherosclerosis2-Risk factors,Microorganisms,Medications,Classification,Surgi...
Atherosclerosis2-Risk factors,Microorganisms,Medications,Classification,Surgi...
varinder kumar
 
Cardiac medications nursing review 2011
Cardiac medications nursing review 2011Cardiac medications nursing review 2011
Cardiac medications nursing review 2011MicheleMSNCCRN
 
Cardiac Medications Review 2011
Cardiac Medications Review 2011Cardiac Medications Review 2011
Cardiac Medications Review 2011MicheleMSNCCRN
 
CARDIOVASCULAR PHARMACOLOGY.ppt
CARDIOVASCULAR PHARMACOLOGY.pptCARDIOVASCULAR PHARMACOLOGY.ppt
CARDIOVASCULAR PHARMACOLOGY.ppt
MulatuAsfaw
 
Antihypertensive drugs.pdf
Antihypertensive drugs.pdfAntihypertensive drugs.pdf
Antihypertensive drugs.pdf
AxmedXBullaale
 
Antihypertensive mbbs copy
Antihypertensive mbbs   copyAntihypertensive mbbs   copy
Antihypertensive mbbs copy
Divya Krishnan
 
Beta blockers and calcium channel blockers
Beta blockers and calcium channel blockersBeta blockers and calcium channel blockers
Beta blockers and calcium channel blockersUma Binoy
 
Diploma 2nd yr PHARMACOLOGY chapter 5 part 1.pdf
Diploma 2nd yr PHARMACOLOGY chapter 5 part 1.pdfDiploma 2nd yr PHARMACOLOGY chapter 5 part 1.pdf
Diploma 2nd yr PHARMACOLOGY chapter 5 part 1.pdf
Sumit Tiwari
 
Antianginal Drugs.pdf
Antianginal Drugs.pdfAntianginal Drugs.pdf
Antianginal Drugs.pdf
Jasmine Chaudhary
 
NurseReview.Org - Antihypertensives Updates (pharmacology review notes)
NurseReview.Org - Antihypertensives Updates (pharmacology review notes)NurseReview.Org - Antihypertensives Updates (pharmacology review notes)
NurseReview.Org - Antihypertensives Updates (pharmacology review notes)
jben501
 
Antihypertensives
AntihypertensivesAntihypertensives
Antihypertensivesraj kumar
 
Management of heart failure 23.02.24.pptx
Management of heart failure 23.02.24.pptxManagement of heart failure 23.02.24.pptx
Management of heart failure 23.02.24.pptx
christina388422
 
ANTI HYPERTENSIVE DRUG
ANTI HYPERTENSIVE DRUGANTI HYPERTENSIVE DRUG
ANTI HYPERTENSIVE DRUG
Akshit Naveria
 
Adrenergic-Blocking Drugs
Adrenergic-Blocking DrugsAdrenergic-Blocking Drugs
Adrenergic-Blocking Drugsshabeel pn
 
Hypertension.pptx
Hypertension.pptxHypertension.pptx
Hypertension.pptx
Safoora Qureshi
 

Similar to Drugs affecting the circulatory system (20)

Common Medications
Common MedicationsCommon Medications
Common Medications
 
Cardio Vascular Drugs
Cardio Vascular Drugs Cardio Vascular Drugs
Cardio Vascular Drugs
 
Cardiac Medications #4 08
Cardiac Medications #4 08Cardiac Medications #4 08
Cardiac Medications #4 08
 
1. Anti hypertensive drugs.pptx what's hypertension
1. Anti hypertensive drugs.pptx what's hypertension1. Anti hypertensive drugs.pptx what's hypertension
1. Anti hypertensive drugs.pptx what's hypertension
 
Atherosclerosis2-Risk factors,Microorganisms,Medications,Classification,Surgi...
Atherosclerosis2-Risk factors,Microorganisms,Medications,Classification,Surgi...Atherosclerosis2-Risk factors,Microorganisms,Medications,Classification,Surgi...
Atherosclerosis2-Risk factors,Microorganisms,Medications,Classification,Surgi...
 
Cardiac medications nursing review 2011
Cardiac medications nursing review 2011Cardiac medications nursing review 2011
Cardiac medications nursing review 2011
 
Cardiac Medications Review 2011
Cardiac Medications Review 2011Cardiac Medications Review 2011
Cardiac Medications Review 2011
 
CARDIOVASCULAR PHARMACOLOGY.ppt
CARDIOVASCULAR PHARMACOLOGY.pptCARDIOVASCULAR PHARMACOLOGY.ppt
CARDIOVASCULAR PHARMACOLOGY.ppt
 
Antihypertensive drugs.pdf
Antihypertensive drugs.pdfAntihypertensive drugs.pdf
Antihypertensive drugs.pdf
 
Antihypertensive mbbs copy
Antihypertensive mbbs   copyAntihypertensive mbbs   copy
Antihypertensive mbbs copy
 
Beta blockers and calcium channel blockers
Beta blockers and calcium channel blockersBeta blockers and calcium channel blockers
Beta blockers and calcium channel blockers
 
Diploma 2nd yr PHARMACOLOGY chapter 5 part 1.pdf
Diploma 2nd yr PHARMACOLOGY chapter 5 part 1.pdfDiploma 2nd yr PHARMACOLOGY chapter 5 part 1.pdf
Diploma 2nd yr PHARMACOLOGY chapter 5 part 1.pdf
 
Antianginal Drugs.pdf
Antianginal Drugs.pdfAntianginal Drugs.pdf
Antianginal Drugs.pdf
 
NurseReview.Org - Antihypertensives Updates (pharmacology review notes)
NurseReview.Org - Antihypertensives Updates (pharmacology review notes)NurseReview.Org - Antihypertensives Updates (pharmacology review notes)
NurseReview.Org - Antihypertensives Updates (pharmacology review notes)
 
Antihypertensives
AntihypertensivesAntihypertensives
Antihypertensives
 
Management of heart failure 23.02.24.pptx
Management of heart failure 23.02.24.pptxManagement of heart failure 23.02.24.pptx
Management of heart failure 23.02.24.pptx
 
ANTI HYPERTENSIVE DRUG
ANTI HYPERTENSIVE DRUGANTI HYPERTENSIVE DRUG
ANTI HYPERTENSIVE DRUG
 
Adrenergic-Blocking Drugs
Adrenergic-Blocking DrugsAdrenergic-Blocking Drugs
Adrenergic-Blocking Drugs
 
Hypertension.pptx
Hypertension.pptxHypertension.pptx
Hypertension.pptx
 
Week 5 Pharma
Week 5 PharmaWeek 5 Pharma
Week 5 Pharma
 

More from sharon49

Artifacts for ne ts1b
Artifacts for ne ts1bArtifacts for ne ts1b
Artifacts for ne ts1bsharon49
 
Angioplasty
AngioplastyAngioplasty
Angioplastysharon49
 
The heart and heart disease
The heart and heart diseaseThe heart and heart disease
The heart and heart diseasesharon49
 
Digital age march 18
Digital age march 18Digital age march 18
Digital age march 18
sharon49
 
Power point tutorial
Power point tutorialPower point tutorial
Power point tutorial
sharon49
 

More from sharon49 (6)

Artifacts for ne ts1b
Artifacts for ne ts1bArtifacts for ne ts1b
Artifacts for ne ts1b
 
Angioplasty
AngioplastyAngioplasty
Angioplasty
 
Flow
FlowFlow
Flow
 
The heart and heart disease
The heart and heart diseaseThe heart and heart disease
The heart and heart disease
 
Digital age march 18
Digital age march 18Digital age march 18
Digital age march 18
 
Power point tutorial
Power point tutorialPower point tutorial
Power point tutorial
 

Recently uploaded

BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
Nguyen Thanh Tu Collection
 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
camakaiclarkmusic
 
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdfAdversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
Po-Chuan Chen
 
678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf
CarlosHernanMontoyab2
 
Unit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdfUnit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdf
Thiyagu K
 
Polish students' mobility in the Czech Republic
Polish students' mobility in the Czech RepublicPolish students' mobility in the Czech Republic
Polish students' mobility in the Czech Republic
Anna Sz.
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
EugeneSaldivar
 
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdfUnit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Thiyagu K
 
Instructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptxInstructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptx
Jheel Barad
 
Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345
beazzy04
 
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
MysoreMuleSoftMeetup
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
Levi Shapiro
 
Model Attribute Check Company Auto Property
Model Attribute  Check Company Auto PropertyModel Attribute  Check Company Auto Property
Model Attribute Check Company Auto Property
Celine George
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
DeeptiGupta154
 
The approach at University of Liverpool.pptx
The approach at University of Liverpool.pptxThe approach at University of Liverpool.pptx
The approach at University of Liverpool.pptx
Jisc
 
How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...
Jisc
 
Palestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptxPalestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptx
RaedMohamed3
 
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXXPhrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
MIRIAMSALINAS13
 
Operation Blue Star - Saka Neela Tara
Operation Blue Star   -  Saka Neela TaraOperation Blue Star   -  Saka Neela Tara
Operation Blue Star - Saka Neela Tara
Balvir Singh
 
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th SemesterGuidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Atul Kumar Singh
 

Recently uploaded (20)

BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
 
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdfAdversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
 
678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf
 
Unit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdfUnit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdf
 
Polish students' mobility in the Czech Republic
Polish students' mobility in the Czech RepublicPolish students' mobility in the Czech Republic
Polish students' mobility in the Czech Republic
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
 
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdfUnit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdf
 
Instructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptxInstructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptx
 
Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345
 
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
 
Model Attribute Check Company Auto Property
Model Attribute  Check Company Auto PropertyModel Attribute  Check Company Auto Property
Model Attribute Check Company Auto Property
 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
 
The approach at University of Liverpool.pptx
The approach at University of Liverpool.pptxThe approach at University of Liverpool.pptx
The approach at University of Liverpool.pptx
 
How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...
 
Palestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptxPalestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptx
 
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXXPhrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
 
Operation Blue Star - Saka Neela Tara
Operation Blue Star   -  Saka Neela TaraOperation Blue Star   -  Saka Neela Tara
Operation Blue Star - Saka Neela Tara
 
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th SemesterGuidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th Semester
 

Drugs affecting the circulatory system

  • 1. Drugs That Affect the Circulatory System
  • 2.
  • 3.
  • 4.
  • 5. Components and Function of the Circulatory System
  • 6.
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.
  • 21.
  • 22.
  • 23.
  • 24.
  • 25.
  • 26.
  • 27.
  • 28.
  • 29.
  • 30.
  • 31.
  • 32.
  • 33.
  • 34.
  • 35.
  • 36.
  • 37.
  • 38.
  • 39.
  • 40.
  • 41.
  • 42.
  • 43.
  • 44.
  • 45.
  • 46.
  • 47.
  • 48.
  • 49.
  • 50.
  • 51.
  • 52.
  • 53.
  • 54.
  • 55.

Editor's Notes

  1. The heart is divided by partitions into four chambers. What are they? (Answer: right and left atria, and right and left ventricles)
  2. Review the remainder of blood circulation. Venous capillaries merge to form larger veins. Blood returns to the heart via vena cava; enters the right atrium. Right atrium contracts; forces blood into right ventricle. Right ventricle contracts, forces blood to lungs. Blood is oxygenated and returned again to left atrium. What are differences between arteries and veins?
  3. Review the exception: The pulmonary artery carries unoxygenated blood. Review the exception: The pulmonary vein carries oxygenated blood. Discuss the components of the heart that are affected by cardiac medications. Consider muscle contraction, chamber filling, electrical conduction, and rhythm.
  4. Why do these conditions require medication? Explain the effect position and rate of flow of blood has on the client with heart failure.
  5. What types of patients are vulnerable to heart failure?
  6. Review the rationale for various drug classes that affect the heart.
  7. Weight should be obtained daily, early in morning before eating or drinking; the bladder should be empty.
  8. An inotropic drug such as digoxin may be combined with an ACE inhibitor, a beta-blocking agent, and/or a diuretic.
  9. When would a prescription for digoxin immune Fab be used? With digitalis therapy, the rate of heart contraction is slowed. Normal heart rate is 60 to 80 beats per minute.
  10. These medications assist in the treatment of hypertension by suppressing the formation of angiotensin II. The first dose may induce a severe hypotensive reaction. The patient should be closely monitored. The physician may discontinue diuretic agents 2 to 3 days before beginning ACE inhibitor therapy.
  11. ACE inhibitors are excreted through the kidney. These medications may cause a severe decrease in blood pressure and an increase in serum potassium level. These medications should be used with caution for patients with renal compromise or pregnancy-induced hypertension.
  12. Beta-blocking agents can be used alone or in combination with other agents to treat hypertension.
  13. A low incidence of side effects exists with angiotensin II receptor–blocking agents. What are some side effects? (Answer: skin rash, facial edema, insomnia, and myalgia)
  14. These medications are also useful in treating diabetic nephropathy and are usually well tolerated. Valsartan (Diovan) is the only one of the listed medications approved to treat heart failure. The remainder are used to treat hypertension and diabetic nephropathy. If the patient is receiving other drugs for hypertension or heart failure, the physician may decrease the dose or eliminate those drugs.
  15. Aldosterone inhibitor agents include spironolactone, a potassium-sparing diuretic agent. Aldosterone inhibitor agents should not be used for patients with elevated serum potassium levels or decreased renal function. Aldosterone is suspected of causing myocardial remodeling after myocardial infarction. This limits the efficient function of the heart. By inhibiting aldosterone, the heart responds more efficiently and the risk for heart failure is decreased.
  16. Discuss normal sinus rhythm and its rate. Rate for bradycardia: <60 Rate for tachycardia: >100
  17. What disorders or conditions require the use of vasoconstricting agents? (Answer: shock, rhinorrhea, allergic reaction)
  18. Epinephrine is available as an EpiPen.
  19. Vasodilating agents are common medication for home management of angina. Vasodilating agents are often first-line treatment for chest pain in the emergency department. What are the routes of administration? (Answer: sublingual, sustained-release oral tablets and capsules, transdermal, spray, intravenous)
  20. Some medications target the dilation of arteries, increasing cardiac output and tissue perfusion. Some medications target the dilation of veins, easing the work of the ventricles. Some medications target both. Common side effects include postural hypotension, reflex tachycardia, and fluid retention. Nearly one third of patients do not take antihypertensive agents properly.
  21. Most patients have “essential” hypertension (no cause is identified). Other lifestyle issues include the following: obesity, diabetes, arthritis (may affect likelihood of exercise), time constraints Review with students the current American Heart Association blood pressure guidelines (available on the organization’s website). If diet and exercise are not effective, single-drug therapy is begun. If this is not effective, combination therapy is begun with several drugs.
  22. Through vessel dilation, these medications reduce the blood flow and workload of the vessels and the heart. Why is orthostatic hypotension a common side effect for this class of drugs?
  23. Clonidine also may be used to control impulsivity in the hyperactive child or the child with attention deficit disorder. It does not increase school performance. Side effects of Aldomet are drowsiness, impotence, and gynecomastia.
  24. Alpha-blocking agents include prazosin hydrochloride (Minipress), terazosin hydrochloride (Hytrin), and doxazosin mesylate (Cardura). Alpha-blocking agents are also used to treat benign prostatic hypertrophy (BPH) or hyperplasia.
  25. These medications affect peripheral arterioles, arteries and arterioles of the heart, and cardiac muscle. They have no effect on the veins. These medications also affect the sites of the electrical conduction of the heart: the SA and AV nodes.
  26. These medications must be used carefully with digoxin. How does the action of beta-blocking agents differ from calcium channel–blocking agents? Common side effects include bradycardia, AV block, exacerbation of heart failure, reflex tachycardia, dizziness, and peripheral edema.
  27. Calcium salts include calcium gluconate, calcium chloride, and calcium lactate.
  28. Drugs include the following: Phytonadione (vitamin K 1 oxide), (Mephyton) Phytonadione injection (AquaMEPHYTON) Administered by the oral or intravenous route. Intravenous administration may cause a severe adverse reaction. Vitamin K injection is administered at birth because infants are bone deficient in vitamin K and are at risk for neonatal hemorrhage.
  29. Prothrombin time (PT) is used to evaluate the effectiveness of warfarin and guard against overdose. International normalized ratio (INR) is a system of standardizing the PT values. What is meant when patients say they take a “blood thinner”? How does an anticoagulant agent “thin” the blood?
  30. Subcutaneous administration is seldom used because of the risk for bruising and bleeding. Heparin is used for prevention and treatment of pulmonary embolism, arterial emboli, and treatment of consumption coagulopathies (like disseminated intravascular coagulation [DIC]). Heparin encourages the antithrombin activity by altering the thrombin part of the clotting cascade.
  31. The lab value activated partial thromboplastin time (aPTT) is used to monitor response to therapy and coagulation. Normal aPTT is approximately 40 seconds. Treatment range for aPTT is usually between 60 and 80 seconds (depends on the patient situation). Review the patient situations that would require heparin treatment. What are the signs and symptoms of the side effects of heparin?
  32. Advantages over unfractionated heparin agents: May be given by subcutaneous injection Have a longer half-life, and thus may be administered less frequently Lower incidence of antiplatelet formation and HIT May be given on a fixed schedule. No need to monitor aPTT because of the low molecular weight. Low–molecular-weight heparin is more expensive than heparin, but many patients can remain at home and self-administer this treatment.
  33. The dose is based on body weight. This medication may be given as prophylaxis to prevent deep vein thrombosis. It may be used to treat an active deep vein thrombosis. Review with students the patient teaching regarding subcutaneous administration, home care, and use of this medication.
  34. Lepirudin directly inhibits thrombin formation. It is used to reverse HIT while maintaining the anticoagulation in the patient. Common side effects include back pain, nausea, hypotension, and hemorrhage.
  35. Heparin must be given for initial treatment while coumarin is being started. Neither large loading doses nor administration using the intramuscular or intravenous route hastens antithrombotic action.
  36. Dose may be adjusted by using the PT or INR.
  37. This therapy is used for acute myocardial infarction, deep vein thrombosis, and massive pulmonary emboli. For myocardial infarction treatment, therapy must be administered within 4 to 6 hours of symptom presentation. Common side effects include hemorrhage, antibody production, fever, and hypotension.
  38. These medications prevent thrombus formation in the arteries. An anticoagulant agent is used to prevent thrombus formation in the veins. They are useful for the prevention of a myocardial infarction (either initial or recurring). They are useful for decreasing the risk for stroke for patients with history of transient ischemic attacks (TIAs).
  39. These medications increase the risk of gastrointestinal bleeding and also increase the risk of hemorrhage and hemorrhagic stroke.
  40. Present guidelines recommend obtaining a complete lipoprotein and triglyceride profile every 5 years beginning at age 20. A low blood cholesterol level is unattainable for many patients using diet alone. Atherosclerosis is the fatty streak in the arterial wall. Atherosclerosis encourages fibrin formation and subsequent thrombi.
  41. Many lipid-lowering drugs must be taken later in the day, with the evening meal. Some drugs decrease production of cholesterol. Others increase the removal of cholesterol from the bloodstream.
  42. Lab testing of lipid levels and liver enzymes is necessary.